and in some instances integrated HBV-DNA was detected in the genome of tumour cells (Popper et al., 1987; Brechot et al., 1981 Brechot et al., , 1983 . Following reports that hepatic HBV-DNA could be detected in non-tumorous tissue and in chronic HBV carriers (Shafritz et al., 1981; Brechot et al., 1982) , it was suggested that detection of integrated HBV-DNA might define patients at risk of developing HCC.
Frequency of hepatic HBV-DNA in Epidemiological studies based on serum markers have implicated the hepatitis B virus (HBV) in the aetiology of hepatocellular carcinoma (HCC) (Szmuness et al., 1978; Beasley, 1982) and in some instances integrated HBV-DNA was detected in the genome of tumour cells (Popper et al., 1987; Brechot et al., 1981 Brechot et al., , 1983 . Following reports that hepatic HBV-DNA could be detected in non-tumorous tissue and in chronic HBV carriers (Shafritz et al., 1981; Brechot et al., 1982) , it was suggested that detection of integrated HBV-DNA might define patients at risk of developing HCC.
We are currently undertaking a large prospective study of cirrhotic patients aimed at delineating risk factors such as the presence of serum markers of HBV infection, which may be associated with an increased risk of malignant change. In view of reports that hepatic HBV-DNA could occasionally be detected even in the absence of conventional serum markers (Vergani et al., 1982; Brechot et al., 1985) , it became important to assess the frequency of hepatic HBV-DNA in relation to HBV serum markers. We now present our findings on hepatic HBV-DNA in a series of 156 biopsies from cirrhotic patients with various forms of long established liver disease including HCC.
Material and methods
Liver biopsies were performed on 156 patients, the majority of whom were of Northern European extraction (102, 65.4%), while the remainder were from Southern Europe and other Mediterranean regions (39, 25%), Arabian and Asian subcontinent (10, 6.4%), the Far East (3, 1.9%) and Africa (2, 1.3%). One hundred and two were male and 54 female. All (Wahl et al., 1979) . At this point cloned HBV-DNA labelled with 32P-deoxycytidine triphosphate by nick translation (Rigby et al., 1977) Following the manufacturer's instructions for stringent washing, blots were autoradiographed in Kodak cassettes fitted with fine intensifying screens using Kodak X-OMAT AR film for up to 7 days at -70'C (Lasky & Mills, 1977 (Table II) . Among the 18 HCC patients two were HBsAg/HBeAg positive. One of them showed replicating sequences, the other showed both episomal/replicating and integrated forms. Of the five HBsAg/anti-HBe positives, three had both forms and one had integrated forms only. There were six subjects with markers of past infection. Five of these showed no sequences, but one (patient C), who was seropositive for both anti-HBs and anti-HBc, showed high molecular weight HBV-DNA at approximately 8.0 kbp (Figure 1, patient C, lanes 1, 2, 3) . This was reprobed with 32P-radiolabelled plasmid and found to be negative, indicating no contamination from vector DNA. No HBV-DNA was detected among the remaining five patients. One patient within this group had both tumour and non-tumour tissue examined and in the presence of serum HBsAg/anti-HBe, both integrated and replicating forms were found in the tumour, but only replicating forms in the non-tumour tissue.
Among those six patients in whom no HBV-DNA sequences could be detected despite the presence of HBeAg, there were two patients who were seropositive for infection, two on antiviral therapy and two others who were seronegative for DNA polymerase activity.
Discussion
As expected, we found a significantly higher prevalence of hepatic HBV-DNA in the surface antigen positive group than in the seronegative group. Indeed, among 115 subjects who were HBsAg seronegative, only one, albeit with HCC, showed HBV-DNA sequences in the liver. This contrasts with earlier studies reported by Brechot et al. (1982, 1983, 1985) and Nalpas et al. (1985) , who detected HBV-DNA sequences, in the absence of conventional seropositivity, in approximately 27% of patients with chronic liver disease and 93% of patients with HCC. Our results are in accord with recent studies on HBsAg seronegative alcoholic liver disease by Walter et al. (1988) , who investigated 47 patients (17 of whom had HCC), and Fong et al. (1988) , who studied 47 biopsies (five from patients with HCC). Both studies failed to detect HBV-DNA in these liver specimens. Pontisso et al. (1987) , in a similar study of 50 HBsAg seronegative subjects, reported that of 42 patients with chronic liver disease, two had HBV-DNA in the liver and one of these showed markers of past infection. Among their eight patients with HCC, one had HBV-DNA in the presence of anti-HBs and anti-HBc, but had been HBsAg positive 4 years previously (Giacchino et al., 1987) . Similarly Harrison et al. (1986) , in a large series involving 160 patients, concluded that there was no evidence to implicate HBV in the pathogenesis of HCC in the absence of HBV seropositivity. It is possible that the DNA sample from patient C contained dimeric HBV-DNA without an EcoRl site, in which case the HBV-DNA would have migrated to the same position in each lane; we have noted the same phenomenon previously (Fagan et al., 1986 ). This would not have been expected if the HBV-DNA were integrated. Certainly the specificity of these bands was confirmed by probing with vector, and the activities of EcoRl and Hind III by observation of ethidium bromide stained DNA digests.
Other investigators (Hino et al., 1985; Fowler et al., 1986; Pasquinelli et al., 1986) have been unable to detect hepatic HBV-DNA in the absence of serum markers or HBV-RNA transcripts (Yokosuka et al., 1986) . A similar situation occurred when using immuno-histochemistry Tur-Kaspa et al., 1986) and in situ hybridisation in combination with molecular hybridisation (Blum et al., 1983) . Liver HBV-DNA sequences have been detected in patients with putative NANB hepatitis (Figus et al., 1984 ), but we, like Harrison et al. (1986) , were unable to confirm these findings in any of our nine presumed NANB patients.
We cannot be certain why in six of our HBsAg/HBeAg, with presumed replicating virus, we could detect no hepatic HBV-DNA sequences. However, two patients were positive for 6 virus infection, which has been shown to suppress HBV viral replication, either as a concurrent or as a superimposed infection (Rizetto et al., 1984) ; one of two patients treated with interferon, which has been reported as a successful antiviral agent (Dusheiko et al., 1986; Alexander et al., 1987) , cleared HBeAg from the serum within one year. Two other patients were serum DNA polymerase negative, and thus might have been clearing the virus spontaneously. Another explanation may be the unequal distribution of cellular HBV throughout the liver (Ogata et al., 1988) , as well as the possibility of biopsy sampling error. However, if this occurred it was consistent throughout, as the percentages of liver HBV-DNA in the different populations/high risk groups closely parallels the frequency of HBsAg seropositivity.
The intimate epidemiological association between HBV infection and HCC development (Nordenfeldt et al., 1982) , and the high incidence of HCC in HBV related cirrhosis (Arthur et al., 1984) have led to suggestions that HBV represents an oncogenic agent in the human liver. Against this, is the observation that non-hepatic tissues and cells which contain the HBV genome, albeit in fewer numbers do not seem prone to malignant transformation (Lie-Injo et al., 1983; Davison et al., 1987) . It has been suggested (Gu, 1988) that the integration of HBV-DNA into the host chromosomes corresponds to an initiation event similar to that found in experimental carcinogenesis when using aflatoxin Bi or diethylnitrosamine. This on its own need not cause transformation, but any continuous stimulation of cell proliferation and its subsequent cell division might cause integrated HBV-DNA to become susceptible to a disarrangement of molecular sequences, causing clonal expansion and initiating malignant transformation (Berman, 1988) .
From our results, it appears that in order to elucidate the mechanism of HBV and its action at molecular level, emphasis must be placed on the investigation of those subjects in whom serum markers of HBV infection can be demonstrated. It is clear from this and other recent studies that there is currently little evidence to implicate HBV in the pathogenesis of HCC in the absence of serum markers, although this situation may change when more sensitive techniques such as the polymerase chain reaction (PCR) are applied.
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